Overview

ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma

Status:
Completed

Trial end date:
2021-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to define the dose-limiting toxicities and maximum tolerated dose of the poly ADP-ribose polymerase inhibitor niraparib and escalating doses of temozolomide and/or irinotecan in patients with pre-treated incurable Ewing sarcoma.

Phase:

Phase 1

Details

Lead Sponsor:

Sarcoma Alliance for Research through Collaboration

Treatments:

Camptothecin
Dacarbazine
Irinotecan
Niraparib
Poly(ADP-ribose) Polymerase Inhibitors
Temozolomide